Mounjaro®
Starting from £179.99/mo
Start journey Learn moreOn semaglutide day one, most people feel almost nothing — and that surprises them. The first dose of Wegovy is 0.25mg, a level chosen entirely for tolerability rather than effect, so dramatic changes in appetite or weight are not what this injection is designed to deliver on day one. It is a prescription-only medicine that requires clinical assessment before any prescriber issues it. Here is what the first day actually involves, and why the most common expectation about it is the one most worth correcting.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It is easy to understand where this expectation comes from. Clinical trial results for semaglutide are striking — the STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. That figure travels. What travels less well is the word "weeks", specifically how many of them come before the medicine is doing its full work.
On day one you receive 0.25mg. That dose does not reduce appetite meaningfully for most people. Its job is to let your gut and nervous system meet semaglutide without the wave of nausea that a higher starting dose would almost certainly cause. Think of it as an introduction rather than a treatment. The therapeutic work begins later, as the dose is titrated upward every four weeks or so under prescriber guidance.
Patients who inject on a Friday and step on the scales on Saturday are measuring the wrong thing. The ones who do well tend to be the ones who understand from the start that day one is groundwork, and if you want to know exactly what to expect when that first injection day arrives, our guide to day one of Wegovy walks through the experience in detail. If you want a fuller picture of the treatment itself before you begin, the Wegovy overview at nume covers the full licensed schedule and what the evidence shows at each stage.
Some people genuinely notice nothing. Others report a mild heaviness in the stomach a few hours after injecting, occasionally some nausea or looser stools, and sometimes a slight tiredness. These are the GI effects the NHS semaglutide page lists as common (nausea, diarrhoea, constipation, indigestion, stomach discomfort) and for most people they are mild and short-lived. They tend to be more noticeable after each dose increase than at the 0.25mg start.
A practical note on timing: many people choose to inject in the evening so that any mild queasiness passes overnight. Others inject on a Monday because the working week makes it easier to remember. There is no medically superior day of the week; consistency matters more than the day you pick, and your prescriber or the Patient Information Leaflet is the right place to check guidance on rotating injection sites and technique.
Injection sites for Wegovy are the abdomen, thigh, or upper arm. Rotating between them reduces the chance of localised skin reactions. If you are new to self-injection, the leaflet that comes with your pen walks through the steps in detail, follow it rather than any online summary, including this one.
One thing worth knowing: semaglutide stays active in your body for around a week after each dose, which is why it is given weekly. That also means a single missed dose rarely undoes progress, though if you are unsure what to do after a delay, the guide to late Wegovy doses covers what to check.
The value of day one is not the 24 hours themselves. It is the habit, the same day each week, the pen in the fridge, the injection before you sit down to eat. People who find the routine straightforward from the start tend to stay consistent, and consistency is what the trial results are built on.
The appetite changes that make semaglutide distinctive (the sense of fullness arriving sooner, the background noise of hunger quietening) typically become noticeable somewhere between weeks two and eight for most people, though individual experience varies. Some notice a small shift in their appetite within the first week; others do not feel a meaningful difference until the dose increases.
If you are curious about how the experience evolves in the days immediately following, the day two and day three pages describe what tends to change as the first week unfolds. For a broader look at how semaglutide works as a medicine, the semaglutide overview explains the mechanism and the evidence base in full.
Wegovy is a prescription-only medicine. A prescriber reviews your health information before any treatment is issued, that clinical step is not a formality, it is how the medicine is kept safe. If you are considering starting, our free consultation is the place to begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.